Abstract: The present invention aims to provide an external dermal composition for anti-ageing, which prevents or improves apparent skin problems such as age-related or senescent wrinkles, fine wrinkles, saggings, spots, etc., as well as maintaining or enhancing the skin barrier functions. The object is solved by providing an external dermal agent for anti-ageing, which contains as an effective ingredient(s) one or more members selected from the group consisting of adenosine N1-oxide 5?-phosphate, analogs thereof, and their salts.

Abstract: The present invention has an object to provide an effective and safe therapeutic agent for inflammatory diseases such as sepsis, hepatitis, and inflammatory bowel disease, and solves the above object by providing a therapeutic agent for inflammatory diseases containing adenosine N1-oxide or a derivative thereof as an effective ingredient.

Abstract: The present invention aims to provide an external dermal composition for anti-ageing, which prevents or improves apparent skin problems such as age-related or senescent wrinkles, fine wrinkles, saggings, spots, etc., as well as maintaining or enhancing the skin barrier functions. The object is solved by providing an external dermal agent for anti-ageing, which contains as an effective ingredient(s) one or more members selected from the group consisting of adenosine N1-oxide 5?-phosphate, analogues thereof, and their salts.

Abstract: The present invention has an object to provide an effective and safe therapeutic agent for inflammatory diseases such as sepsis, hepatitis, and inflammatory bowel disease, and solves the above object by providing a therapeutic agent for inflammatory diseases containing adenosine N1-oxide or a derivative thereof as an effective ingredient.

Abstract: The present invention has an object to provide an effective and safe therapeutic agent for inflammatory diseases such as sepsis, hepatitis, and inflammatory bowel disease, and solves the above object by providing a therapeutic agent for inflammatory diseases containing adenosine N1-oxide or a derivative thereof as an effective ingredient.

Abstract: The present invention has an object to provide a mouthwash composition for preventing and/or treating periodontal diseases safely and effectively. The present invention solves the above object by providing a mouthwash composition for preventing and/or treating periodontal diseases, characterized in that it comprises, as an effective ingredient(s), one or more members selected from the group consisting of adenosine N1-oxide, 3?-glucosyladenosine N1-oxide, 5?-glucosyladenosine N1-oxide, 5?-adenosine diphosphate N1-oxide, and 5?-adenosine triphosphate N1-oxide but does not contain any saccharide assimilable by periodontal disease bacteria.

Abstract: The present invention has an object to provide a mouthwash composition for preventing and/or treating periodontal diseases safely and effectively. The present invention solves the above object by providing a mouthwash composition for preventing and/or treating periodontal diseases, characterized in that it comprises, as an effective ingredient(s), one or more members selected from the group consisting of adenosine N1-oxide, 3?-glucosyladenosine N1-oxide, 5?-glucosyladenosine N1-oxide, 5?-adenosine diphosphate N1-oxide, and 5?-adenosine triphosphate N1-oxide but does not contain any saccharide assimilable by periodontal disease bacteria.

Abstract: A protein which induces the IFN-? production by immunocompetent cells and has a molecular weight of 19,000±5,000 daltons on SDS-PAGE or gel filtration method and a pI of 4.8±1.0 on chromatofocusing. The protein is isolated from mouse liver and can be purified by a monoclonal antibody specific to it. The monoclonal antibody can be also used for assaying the protein.

Abstract: The present invention has an object to provide an effective and safe therapeutic agent for inflammatory diseases such as sepsis, hepatitis, and inflammatory bowel disease, and solves the above object by providing a therapeutic agent for inflammatory diseases containing adenosine N1-oxide or a derivative thereof as an effective ingredient.

Abstract: The present invention has an object to provide an effective and safe therapeutic agent for inflammatory diseases such as sepsis, hepatitis, and inflammatory bowel disease, and solves the above object by providing a therapeutic agent for inflammatory diseases containing adenosine N1-oxide or a derivative thereof as an effective ingredient.

Abstract: An object of the present invention is to provide anti-inflammatory agent having an excellent effect and less adverse side-effects. The object is attained by providing an anti-inflammatory agent comprising 2-aminophenol or a derivative thereof as an effective ingredient.

Abstract: A protein which induces the IFN-? production by immunocompetent cells and has a molecular weight of 19,000±5,000 daltons on SDS-PAGE or gel filtration method and a pI of 4.8±1.0 on chromatofocusing. The protein is isolated from mouse liver and can be purified by a monoclonal antibody specific to it. The monoclonal antibody can be also used for assaying the protein.

Abstract: A monoclonal antibody which is specific to a polypeptide having a molecular weight of 18,500±3,000 daltons on SDS-PAGE and a pI of 4.9±1.0 on chromatofocusing. The monoclonal antibody is obtainable from hybridomas and can be used for the purification and detection of the polypeptide. The polypeptide strongly induces the IFN-? production by immunocompetent cells with only a small amount, and dose not cause serious side effects even when administered to human in a relatively-high dose.

Abstract: A human IFN-? inducing polypeptide and its nucleotide sequence was isolated, purified and characterized. Pharmaceutical compositions containing this novel INF-? inducing polypeptide or active fragments thereof are formulated and monoclonal antibodies are raised against this polypeptide or antigenic fragments thereof. The polypeptide can be used in a method for treating diseases susceptive to treatment with INF-?, and methods for enhancing the cytotoxicity of NK cells or for inducing the formation of LAK cells, such as to treat tumors and malignant pathologies.

Abstract: It is intended to provide an anti-allergic agent, which efficaciously relieves symptoms accompanying an allergic disease without causing any serious side effect. This object is achieved by providing an anti-allergic agent which contains, as an effective ingredient, proteins collected from royal jelly or purified royal jelly, or royal jelly or purified royal jelly containing the proteins.

Abstract: A human IFN-? inducing polypeptide and its nucleotide sequence was isolated, purified and characterized. Pharmaceutical compositions containing this novel INF-? inducing polypeptide or active fragments thereof are formulated and monoclonal antibodies are raised against this polypeptide or antigenic fragments thereof. The polypeptide can be used in a method for treating diseases susceptive to treatment with INF-?, and methods for enhancing the cytotoxicity of NK cells or for inducing the formation of LAK cells, such as to treat tumors and malignant pathologies.

Abstract: A human IFN-? inducing polypeptide and its nucleotide sequence was isolated, purified and characterized. Pharmaceutical compositions containing this novel IFN-? inducing polypeptide or active fragments thereof are formulated and monoclonal antibodies are raised against this polypeptide or antigenic fragments thereof. The polypeptide can be used in a method for treating diseases susceptive to treatment with IFN-?, and methods for enhancing the cytotoxicity of NK cells or for inducing the formation of LAK cells, such as to treat tumors and malignant pathologies.

Abstract: It is intended to provide an anti-allergic agent, which efficaciously relieves symptoms accompanying an allergic disease without causing any serious side effect. This object is achieved by providing an anti-allergic agent which contains, as an effective ingredient, proteins collected from royal jelly or purified royal jelly, or royal jelly or purified royal jelly containing the proteins.

Abstract: A monoclonal antibody which is specific to a polypeptide having a molecular weight of 18,500±3,000 daltons on SDS-PAGE and a pI of 4.9±1.0 on chromatofocusing. The monoclonal antibody is obtainable from hybridomas and can be used for the purification and detection of the polypeptide. The polypeptide strongly induces the IFN-&ggr; production by immunocompetent cells with only a small amount, and dose not cause serious side effects even when administered to human in a relatively-high dose.

Abstract: A protein which induces the IFN-&ggr; production by immunocompetent cells and has a molecular weight of 19,000±5,000 daltons on SDS-PAGE or gel filtration method and a pI of 4.8±1.0 on chromatofocusing. The protein is isolated from mouse liver and can be purified by a monoclonal antibody specific to it. The monoclonal antibody can be also used for assaying the protein.